A case analysis published online October 12, 2026 in the Journal of the American Academy of Dermatology argues that severe cutaneous adverse events following enfortumab vedotin should be classified as toxic erythema of consolidation (TEC) rather than toxic epidermal necrolysis (TEN).

The paper, authored by Rentao Yu, Ling Gu, Qian Wu, Yun Pan, Fengzeng Li, and Aijun Chen, carries the title "Re-evaluating Severe Cutaneous Adverse Events to Enfortumab Vedotin: TEC rather than TEN." It revisits how dermatologists categorize the dramatic blistering and desquamating eruptions that can develop in patients receiving the antibody-drug conjugate, which targets Nectin-4 and is used in urothelial carcinoma.

Why does the TEC-versus-TEN distinction matter?

TEN carries a high mortality burden and typically triggers aggressive interventions, including withdrawal of all suspect drugs, admission to burn units, and consideration of immunosuppressive therapy. If enfortumab vedotin–associated reactions mimic TEN histologically and clinically but follow a different pathomechanism — drug delivery to the skin epithelium rather than an immune-mediated process — then classification as TEC changes both prognosis and management.

The authors' central claim is that these reactions are not classic TEN. Recognition of TEC matters because TEC lesions generally reflect direct epithelial toxicity from the drug conjugate rather than the apoptosis-driven, immune-mediated epidermal necrosis that defines TEN. Mislabeling these events as TEN could lead clinicians to permanently discontinue an effective oncology drug or escalate to treatments that offer no benefit for this reaction pattern.

How should dermatologists respond?

For dermatologists consulted on patients receiving enfortumab vedotin who develop widespread epidermal detachment, blistering, or dusky erythema, the analysis signals that the differential should explicitly include TEC. The clinical phenotype can overlap substantially with TEN, and the published title indicates the authors conclude the consolidation-type reaction is the more accurate diagnosis for these events.

The study appeared in JAAD, placing the reclassification argument before the dermatology readership most likely to encounter these consultations as enfortumab vedotin use in urothelial cancer expands. The authors — spanning Rentao Yu, Ling Gu, Qian Wu, Yun Pan, Fengzeng Li, and Aijun Chen — frame the work as a re-evaluation, suggesting the case material supports moving away from the TEN label for this drug's severe cutaneous reactions.

Whether the proposed reclassification gains acceptance will depend on additional case series and, potentially, histopathologic criteria that reliably separate TEC from TEN at the bedside; expect this paper to inform consultation practice on antibody-drug conjugate toxicities in the interim.